Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Specimen Handling 648pembrolizumab 606Magnetic Resonance Spectroscopy 559Carboplatin 446Cyclophosphamide 394Cisplatin 394Biopsy 376Nivolumab 325Paclitaxel 324Gemcitabine 317Radiotherapy 295Bevacizumab 245Dexamethasone 224fludarabine 214Docetaxel 202durvalumab 194Oxaliplatin 191venetoclax 187atezolizumab 179Fluorouracil 179Rituximab 174Capecitabine 170Pemetrexed 169Radiation 164Doxorubicin 164Radiosurgery 161Ipilimumab 148Lenalidomide 143Leucovorin 139Etoposide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pirarubicin × 90 days × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡